Renal Cancer VL

The ORACLE Study: The Efficacy of Combination Systemic Therapies in Patients with Non-Clear Cell Renal Cell Carcinoma - Deepak Kilari

Details
Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...

Atezolizumab as Adjuvant Therapy After Resection for Patients with Renal Cell Carcinoma with Increased Risk of Recurrence: IMmotion010 Trial, Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Lancet publication Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Approximately 80% of patients, present initially with local regional disease. However, despite the i...

Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad Sadeghi

Details
Sarmad Sadeghi and Pedro Barata discuss the results of a randomized Phase II that explored OX40in combination with axitinib in patients with renal cell carcinoma. Patients in the trial had progressive disease after receiving immunotherapy with the usual PD-1/PD-L1 antibodies. The primary endpoint was progression-free survival. Dr. Sadeghi describes the rationale for the trial design, why the trial...

Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges

Details
Laurence Albiges joins Pedro Barata highlighting the phase 2 KEYNOTE-B61 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). This is an area of unmet need and during the ESMO 2022 meeting, Dr. Albiges presented study data for the first time. KEYNOTE-B61 enroll patients with non-clear cell histology that have never been pre...

Why Not Biopsy? Challenging the Status Quo in Renal Mass Management - Jaime Landman

Details
Ralph Clayman converses with Jaime Landman about the controversial practice of biopsying renal masses, a topic that has stirred significant debate within the medical community. Dr. Landman elucidates the merits of Biopsy Informed Active Surveillance (BIAS), a departure from the existing renal mass guidelines that he argues are largely culture-based rather than data-driven. Dr. Landman highlights t...

How Office-Based Renal Biopsies Could Upend Current Urological Guidelines - Jaime Landman

Details
Monty Pal and Jaime Landman discuss Landman's groundbreaking article on office-based renal mass biopsies. Dr. Landman elaborates on his decade-long journey to develop the technique, similar to prostate biopsies, that can significantly impact kidney cancer treatment decisions. He shares results from a multicenter trial involving 72 patients, demonstrating the feasibility and benefits of office-base...

Superfluous Hospital Expenditure Associated with Unnecessary Renal Cyst Surveillance - Lee Ponsky & Laura Bukavina

Details
In this episode of Kidney Cancer Today, Monty Pal and Jamie Landman team up with Laura Bukavina and Lee Ponsky to discuss consults for benign renal cysts undergoing unnecessary active surveillance. Among other topics, their conversation especially touches on present flaws in the healthcare system, including the appropriate evaluation of renal cysts and healthcare disparities in accessibility to ac...

CT Guided Percutaneous Renal Mass Cryoablation - Daniel Watson

Details
Daniel Watson and Alan Burns present their collaborative approach in favor of percutaneous renal mass cryoablation for renal masses. To date, Dr. Watson and Burns have done 207 of these procedures. The mean age of the patient is approximately 69 years and the mean size of the lesions is about 2.3 centimeters. Dr. Watson suggests a 85% cure rate with this procedure. Biographies: Daniel L. Watson, M...

Supine PCNL (Ambulatory): Who? What? When? Why? How? - James F. Borin

Details
James Borin speaks about the revolution and the evolution of percutaneous renal surgery. The evolution of the technique is now using ultrasound guidance and smaller scopes, mini-percs with endoscopic guidance. Dr. Borin answers the following questions during his presentation: who can have a supine PCNL? What is it?, and When should it be done ambulatory? He also describes what he calls a hybrid pr...

Outpatient Renal Procedures - Ashley Baker

Details
Ashley Baker presents on percutaneous renal biopsy in the ambulatory surgery center. Dr. Baker presents in favor of urologists being involved and of the safety of the procedure being performed in the ambulatory surgery center. Biographies: Ashley Baker, MD, Urology Specialist, Shreveport, Louisiana, USA. Moderator: Evan R. Goldfischer, MD, MBA Related Content: Biopsy of the Small Renal Mass - Stil...